Tae Woo Jung Selected Research

Palmitates

5/2022	Ginsenoside compound K ameliorates palmitate-induced atrophy in C2C12 myotubes via promyogenic effects and AMPK/autophagy-mediated suppression of endoplasmic reticulum stress.
12/2021	Dimethyl itaconate attenuates palmitate-induced insulin resistance in skeletal muscle cells through the AMPK/FGF21/PPARδ-mediated suppression of inflammation.
12/2021	Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
1/2021	Valdecoxib improves lipid-induced skeletal muscle insulin resistance via simultaneous suppression of inflammation and endoplasmic reticulum stress.
1/2021	Capmatinib improves insulin sensitivity and inflammation in palmitate-treated C2C12 myocytes through the PPARδ/p38-dependent pathway.
12/2020	Administration of kynurenic acid reduces hyperlipidemia-induced inflammation and insulin resistance in skeletal muscle and adipocytes.
12/2020	Clinically confirmed DEL-1 as a myokine attenuates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes via AMPK/HO-1- pathway.
11/2020	1,2-Dilinoleoyl-sn-glycero-3-phosphocholine increases insulin sensitivity in palmitate-treated myotubes and induces lipolysis in adipocytes.
1/2020	DEL-1 ameliorates high-fat diet-induced insulin resistance in mouse skeletal muscle through SIRT1/SERCA2-mediated ER stress suppression.
1/2020	Humanin attenuates palmitate-induced hepatic lipid accumulation and insulin resistance via AMPK-mediated suppression of the mTOR pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tae Woo Jung Research Topics

Disease

32	Insulin Resistance 01/2022 - 05/2006
31	Inflammation (Inflammations) 04/2022 - 01/2013
13	Obesity 01/2022 - 10/2013
9	Non-alcoholic Fatty Liver Disease 12/2021 - 10/2013
6	Type 2 Diabetes Mellitus (MODY) 11/2019 - 05/2007
4	Hyperlipidemias (Hyperlipidemia) 12/2020 - 01/2017
4	Atherosclerosis 01/2020 - 01/2013
4	Parkinson Disease (Parkinson's Disease) 02/2007 - 02/2006
4	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2007 - 02/2006
4	Neuroblastoma 02/2007 - 02/2006
2	Rheumatoid Arthritis 01/2022 - 01/2021
2	Osteoarthritis 01/2022 - 01/2021
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 07/2014
2	Mitochondrial Diseases (Mitochondrial Disease) 12/2018 - 02/2007
2	Weight Gain 10/2018 - 01/2017
1	Atrophy 05/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022
1	Cataract (Cataracts) 01/2022
1	Muscle Cramp (Cramp) 01/2022
1	Neuroinflammatory Diseases 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Dysmenorrhea (Menstrual Pain) 01/2021
1	Atopic Dermatitis (Atopic Eczema) 08/2020
1	Glioma (Gliomas) 08/2020
1	Mania (Manias) 01/2020
1	Insulinoma 01/2019
1	Metabolic Diseases (Metabolic Disease) 01/2019
1	Weight Loss (Weight Reduction) 01/2018

Drug/Important Bio-Agent (IBA)

19	PalmitatesIBA 05/2022 - 06/2012
16	Small Interfering RNA (siRNA)IBA 12/2021 - 09/2015
11	Insulin (Novolin)FDA Link 04/2022 - 01/2012
10	LipidsIBA 01/2022 - 11/2015
7	AMP-Activated Protein KinasesIBA 12/2020 - 07/2011
7	Proteins (Proteins, Gene)FDA Link 03/2018 - 05/2007
6	10,17- dihydroxydocosa- 4,7,11,13,15,19- hexaenoic acidIBA 10/2019 - 01/2017
6	Fatty Acids (Saturated Fatty Acids)IBA 10/2018 - 09/2015
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 02/2006
5	AdiponectinIBA 12/2017 - 05/2006
4	Sirtuin 1IBA 12/2021 - 06/2012
4	Messenger RNA (mRNA)IBA 01/2018 - 05/2007
4	JNK Mitogen-Activated Protein KinasesIBA 01/2018 - 09/2015
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018 - 10/2014
4	NeurotoxinsIBA 02/2007 - 02/2006
3	Pharmaceutical PreparationsIBA 04/2022 - 08/2019
3	AcidsIBA 01/2022 - 09/2015
3	Kynurenic Acid (Kynurenate)IBA 01/2021 - 01/2019
3	Adenosine Monophosphate (AMP)IBA 01/2020 - 01/2014
3	LipopolysaccharidesIBA 01/2020 - 11/2018
3	Glucose (Dextrose)FDA LinkGeneric 11/2019 - 01/2017
3	Interleukin-6 (Interleukin 6)IBA 11/2019 - 01/2017
3	Selenoprotein PIBA 10/2019 - 01/2013
3	Docosahexaenoic AcidsIBA 01/2018 - 01/2017
3	Chemotactic FactorsIBA 01/2018 - 09/2015
3	LC15-0444IBA 11/2015 - 07/2014
3	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2015 - 07/2014
3	Rosiglitazone (Avandia)FDA Link 05/2007 - 02/2006
2	capmatinibIBA 04/2022 - 01/2021
2	valdecoxib (Bextra)FDA Link 01/2022 - 01/2021
2	patchouli alcoholIBA 12/2021 - 01/2021
2	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 12/2020 - 01/2019
2	Phosphatidylcholines (Phosphatidylcholine)IBA 11/2020 - 01/2018
2	Peptides (Polypeptides)IBA 08/2020 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	AdipokinesIBA 11/2019 - 10/2014
2	alpha-2-HS-GlycoproteinIBA 10/2019 - 10/2013
2	salicylsalicylic acid (salsalate)IBA 08/2019 - 01/2013
2	Protein Kinases (Protein Kinase)IBA 01/2019 - 01/2014
2	Nonesterified Fatty Acids (NEFA)IBA 01/2019 - 05/2007
2	Triglycerides (Triacylglycerol)IBA 10/2018 - 05/2007
2	CytokinesIBA 01/2018 - 12/2017
2	Lipoxygenase (Lipoxygenase-1)IBA 01/2018 - 01/2017
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 04/2015 - 07/2014
2	1-Methyl-4-phenylpyridinium (1 Methyl 4 phenylpyridinium)IBA 02/2007 - 05/2006
2	AcetaldehydeIBA 08/2006 - 02/2006
1	ginsenoside M1IBA 05/2022
1	Midodrine (Midon)FDA LinkGeneric 01/2022
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022
1	Sorbitol (Yal)FDA Link 01/2022
1	dimethyl itaconateIBA 12/2021
1	DITAIBA 12/2021
1	fibroblast growth factor 21IBA 12/2021
1	KynurenineIBA 12/2020
1	MyokinesIBA 12/2020
1	Tryptophan (L-Tryptophan)FDA Link 12/2020
1	Leucine (L-Leucine)FDA Link 08/2020
1	Neuroprotective AgentsIBA 01/2020
1	LithiumIBA 01/2020
1	humaninIBA 01/2020
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 01/2020
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020
1	Mannose ReceptorIBA 01/2020
1	ginsenoside Rb2IBA 01/2020
1	EnzymesIBA 11/2019
1	Eukaryotic Initiation Factor-2 (EIF 2)IBA 11/2019
1	Inositol (Myoinositol)IBA 11/2019
1	Insulin Receptor Substrate ProteinsIBA 11/2019
1	Cocaine (Cocaine HCl)IBA 12/2018
1	Hypoglycemic Agents (Hypoglycemics)IBA 10/2018
1	LDL Lipoproteins (beta Lipoproteins)IBA 10/2018

Therapy/Procedure

2	Therapeutics 12/2021 - 12/2020